(Bloomberg) -- Blackstone Inc. bought a Kyoto hotel from Goldman Sachs Group Inc. as a rapid tourism rebound in Japan boosts hospitality deals in the island nation. Most Read from BloombergHow Suspects Laundered Billions in Singapore for YearsWall Street’s Furious Bull Run Gets Reality Check: Markets WrapHarvard Alumni Rebuke Its Israel Response With Mere $1 DonationsBitcoin Surges Past $42,000 Even as Stocks and Bonds Take a HitIsrael’s Wider War Has US Cautioning of ‘Strategic Defeat’The 158-r
Private equity firm Blackstone is exploring the sale of Anthos Therapeutics, a developer of a new generation of blood thinners it launched four years ago with backing from Novartis, according to people familiar with the matter. Anthos, which does not yet have any approved products or generate revenue, could be worth several billion dollars in a potential sale, significantly more than the $250 million Blackstone invested when it founded Anthos in 2019, the sources said. Cambridge, Massachusetts-based Anthos' most advanced product, a monoclonal antibody called abelacimab, is intended for patients with atrial fibrillation who do not respond well to other anticoagulants because of heavy bleeding.
NEW YORK (Reuters) -Private equity firm Blackstone is exploring the sale of Anthos Therapeutics, a developer of a new generation of blood thinners it launched four years ago with backing from Novartis, according to people familiar with the matter. Anthos, which does not yet have any approved products or generate revenue, could be worth several billion dollars in a potential sale, significantly more than the $250 million Blackstone invested when it founded Anthos in 2019, the sources said.